iBio, Inc. Common Stock - Asset Resilience Ratio
iBio, Inc. Common Stock (IBIO) has an Asset Resilience Ratio of 33.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IBIO total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how iBio, Inc. Common Stock's Asset Resilience Ratio has changed over time. See iBio, Inc. Common Stock book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down iBio, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IBIO market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $21.46 Million | 33.44% |
| Total Liquid Assets | $21.46 Million | 33.44% |
Asset Resilience Insights
- Very High Liquidity: iBio, Inc. Common Stock maintains exceptional liquid asset reserves at 33.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
iBio, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare iBio, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for iBio, Inc. Common Stock (2013–2023)
The table below shows the annual Asset Resilience Ratio data for iBio, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.00% | $0.00 | $41.21 Million | -- |
| 2022-06-30 | 10.91% | $10.85 Million | $99.41 Million | -2.41pp |
| 2021-06-30 | 13.32% | $19.57 Million | $146.97 Million | -- |
| 2020-06-30 | 0.00% | $0.00 | $94.19 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $43.08 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $36.01 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $51.60 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $12.49 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $6.49 Million | -- |
| 2013-06-30 | 0.00% | $0.00 | $9.35 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more